Trials / Completed
CompletedNCT01730508
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 978 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, prospective, observational study will evaluate the use in clinical practice and the efficacy and safety of Pegasys (peginterferon alfa-2a) in Chinese participants with HBeAg negative chronic hepatitis B. Participants receiving Pegasys according to the local label will be followed for the duration of their treatment and for one year after cessation of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon Alfa (Peginterferon Alfa) | Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling. |
Timeline
- Start date
- 2012-11-20
- Primary completion
- 2017-06-25
- Completion
- 2017-06-25
- First posted
- 2012-11-21
- Last updated
- 2017-07-14
Locations
88 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01730508. Inclusion in this directory is not an endorsement.